Your Article Summary
See Latest ArticlesAdverse effects of therapy for ANCA-associated vasculitis
Best Practice & Research: Clinical Rheumatology, 06/30/09
Turnbull J et al. - The introduction of cyclophosphamide- and prednisolone-based treatment regimens has significantly improved outcome in patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis. Improvements in disease management should include the increased awareness of treatment-related toxicity and its prevention.
Related Articles
European League Against Rheumatism/European Vasculitis Study Group recommendations for the management of vasculitis
Current Opinion in Rheumatology, 10/16/09
Relevance Score: 92%
Resolution of anti-neutrophil cytoplasmic antibody-associated vasculitis after resection of gastric cancer
Modern Rheumatology, 10/19/09
Relevance Score: 91%
Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9
Journal of Rheumatology, 10/20/09
Relevance Score: 89%
Cutaneous vasculitis induced by TNF inhibitors: a report of three cases
Modern Rheumatology, 10/16/09
Relevance Score: 88%
Analysis of T-cell receptor usage in myeloperoxidase-antineutrophil cytoplasmic antibody-associated renal vasculitis
Clinical and Experimental Nephrology, 10/09/09
Relevance Score: 88%
Today in Vasculitic Syndromes...keeping you current
Receive free subspecialty "5-minute updates" via email
Is bioptic assurance reasonable in patients with Sjogren’s syndrome
Zeitschrift für Rheumatologie, 12/19/09
HIV-associated Intracranial Aneurysmal Vasculopathy in Adults
Journal of Rheumatology, 12/17/09
Late response to anti-TNF-alpha therapy in refractory mucocutaneous lesions of Behcets disease
Rheumatology International, 12/17/09